Fig. 2: SRT2104 administration to mdx mice enhances muscle performance and reduces muscle damage. | Cell Death & Disease

Fig. 2: SRT2104 administration to mdx mice enhances muscle performance and reduces muscle damage.

From: The SIRT1 activator SRT2104 exerts exercise mimetic effects and promotes Duchenne muscular dystrophy recovery

Fig. 2

SRT2104 administration in mdx mice improves muscular performances, assessed by exhaustion treadmill running test, measuring distance ran (A left panel) and time to exhaustion (A right panel), as well as force, assessed by WBT test, with WBT 5 (B left panel) and 10 (B right panel), representing respectively the best 5 or the best 10 forward pulling tension normalized on body weight (WT n ≥ 6; mdx veh n ≥ 7; mdx SRT2104 n ≥ 8). Histological analyses in diaphragm (DP) muscle of WT, mdx vehicle, and mdx upon SRT2104 treatment: hematoxylin and eosin (H&E) staining (scale bar = 50 μm) (C); mouse IgG staining labeling myonecrotic fibers (scale bar = 100 μm) (D); CD45 staining to identify immune infiltrate (scale bar = 100 μm) (E). Percentage of myonecrosis area (WT n = 3; mdx veh n = 8; mdx SRT2104 n = 7) and CD45+ fibers relative to mdx vehicle (WT n = 3; mdx veh n = 7; mdx SRT2104 n = 6) are provided. * versus WT mice, (** P < 0.01, *** P < 0.001, **** P < 0.0001). + versus vehicle-treated mdx mice (+ P < 0.05, ++ P < 0.01, +++ P < 0.001). Values are expressed as mean ± SEM.

Back to article page